OBJECTIVE: To develop a simplified and relatively inexpensive version of cartilage proteoglycan-induced arthritis (PGIA), an autoimmunity model of rheumatoid arthritis (RA), and to evaluate the extent to which this new model replicates the disease parameters of PGIA and RA. METHODS: Recombinant human G1 domain of human cartilage PG containing "arthritogenic" T cell epitopes was generated in a mammalian expression system and used for immunization of BALB/c mice. The development and progression of arthritis in recombinant human PG G1-immunized mice (designated recombinant human PG G1-induced arthritis [GIA]) was monitored, and disease parameters were compared with those in the parent PGIA model. RESULTS: GIA strongly resembled PGIA, although the clinical symptoms and immune responses in mice with GIA were more uniform than in those with PGIA. Mice with GIA showed evidence of stronger Th1 and Th17 polarization than those with PGIA, and anti-mouse PG autoantibodies were produced in different isotype ratios in the 2 models. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected in both models; however, serum levels of IgG-RF and anti-CCP antibodies were different in GIA and PGIA, and both parameters correlated better with disease severity in GIA than in PGIA. CONCLUSION: GIA is a novel model of seropositive RA that exhibits all of the characteristics of PGIA. Although the clinical phenotypes are similar, GIA and PGIA are characterized by different autoantibody profiles, and the 2 models may represent 2 subtypes of seropositive RA, in which more than 1 type of autoantibody can be used to monitor disease severity and response to treatment.
OBJECTIVE: To develop a simplified and relatively inexpensive version of cartilage proteoglycan-induced arthritis (PGIA), an autoimmunity model of rheumatoid arthritis (RA), and to evaluate the extent to which this new model replicates the disease parameters of PGIA and RA. METHODS: Recombinant human G1 domain of humancartilage PG containing "arthritogenic" T cell epitopes was generated in a mammalian expression system and used for immunization of BALB/c mice. The development and progression of arthritis in recombinant humanPG G1-immunized mice (designated recombinant humanPG G1-induced arthritis [GIA]) was monitored, and disease parameters were compared with those in the parent PGIA model. RESULTS:GIA strongly resembled PGIA, although the clinical symptoms and immune responses in mice with GIA were more uniform than in those with PGIA. Mice with GIA showed evidence of stronger Th1 and Th17 polarization than those with PGIA, and anti-mousePG autoantibodies were produced in different isotype ratios in the 2 models. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected in both models; however, serum levels of IgG-RF and anti-CCP antibodies were different in GIA and PGIA, and both parameters correlated better with disease severity in GIA than in PGIA. CONCLUSION:GIA is a novel model of seropositive RA that exhibits all of the characteristics of PGIA. Although the clinical phenotypes are similar, GIA and PGIA are characterized by different autoantibody profiles, and the 2 models may represent 2 subtypes of seropositive RA, in which more than 1 type of autoantibody can be used to monitor disease severity and response to treatment.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Paul D Doodes; Yanxia Cao; Keith M Hamel; Yumei Wang; Rachel L Rodeghero; Katalin Mikecz; Tibor T Glant; Yoichiro Iwakura; Alison Finnegan Journal: J Immunol Date: 2009-12-18 Impact factor: 5.422
Authors: Paul A Monach; Wolfgang Hueber; Benedikt Kessler; Beren H Tomooka; Maya BenBarak; Barry P Simmons; John Wright; Thomas S Thornhill; Marc Monestier; Hidde Ploegh; William H Robinson; Diane Mathis; Christophe Benoist Journal: Proc Natl Acad Sci U S A Date: 2009-08-31 Impact factor: 11.205
Authors: Brian A Kidd; Peggy P Ho; Orr Sharpe; Xiaoyan Zhao; Beren H Tomooka; Jennifer L Kanter; Lawrence Steinman; William H Robinson Journal: Arthritis Res Ther Date: 2008-09-30 Impact factor: 5.156
Authors: Cliff Rims; Hannes Uchtenhagen; Mariana J Kaplan; Carmelo Carmona-Rivera; Philip Carlucci; Katalin Mikecz; Adrienn Markovics; Jeffrey Carlin; Jane H Buckner; Eddie A James Journal: Arthritis Rheumatol Date: 2019-03-08 Impact factor: 10.995
Authors: Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman Journal: Expert Rev Vaccines Date: 2015-03-18 Impact factor: 5.217
Authors: Ryan Galea; Hendrik J Nel; Meghna Talekar; Xiao Liu; Joshua D Ooi; Megan Huynh; Sara Hadjigol; Kate J Robson; Yi Tian Ting; Suzanne Cole; Karyn Cochlin; Shannon Hitchcock; Bijun Zeng; Suman Yekollu; Martine Boks; Natalie Goh; Helen Roberts; Jamie Rossjohn; Hugh H Reid; Ben J Boyd; Ravi Malaviya; David J Shealy; Daniel G Baker; Loui Madakamutil; A Richard Kitching; Brendan J O'Sullivan; Ranjeny Thomas Journal: JCI Insight Date: 2019-09-19